The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
出版年份 2012 全文链接
标题
The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels
作者
关键词
Tamoxifen, Endoxifen, Genotype, Phenotype, Dextromethorphan, Breath test
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 71, Issue 3, Pages 593-601
出版商
Springer Nature
发表日期
2012-12-10
DOI
10.1007/s00280-012-2034-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score
- (2012) Alan H. B. Wu et al. BREAST CANCER RESEARCH AND TREATMENT
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
- (2012) Jennifer Gjerde et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers
- (2012) Kerri A. Schoedel et al. CLINICAL DRUG INVESTIGATION
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Alternate Estrogen Receptors Promote Invasion of Inflammatory Breast Cancer Cells via Non-Genomic Signaling
- (2012) Kazufumi Ohshiro et al. PLoS One
- Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
- (2011) Kazuma Kiyotani et al. BREAST CANCER RESEARCH AND TREATMENT
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment
- (2011) Anne-Joy M. de Graan et al. JOURNAL OF CLINICAL ONCOLOGY
- Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
- (2011) William J. Irvin et al. JOURNAL OF CLINICAL ONCOLOGY
- Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes
- (2010) Madhu S. Singh et al. BREAST
- Orally administered Endoxifen is a new therapeutic agent for breast cancer
- (2010) Ateeq Ahmad et al. BREAST CANCER RESEARCH AND TREATMENT
- Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
- (2010) Nava Siegelmann-Danieli et al. BREAST CANCER RESEARCH AND TREATMENT
- Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence
- (2010) Laurent Azoulay et al. BREAST CANCER RESEARCH AND TREATMENT
- Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects
- (2010) A Ahmad et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
- (2009) T. P. Ahern et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor for Degradation in Breast Cancer Cells
- (2009) X. Wu et al. CANCER RESEARCH
- Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry
- (2009) S.F. Teunissen et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Single time point diagnostic breath tests: a review
- (2009) Anil S Modak Journal of Breath Research
- Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer
- (2008) V. O. Dezentje et al. CLINICAL CANCER RESEARCH
- Evaluation of a [13C]-Dextromethorphan Breath Test to Assess CYP2D6 Phenotype
- (2008) J. Steven Leeder et al. JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started